<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7128205/results/search/disease/results.xml">
  <result pre="italic;} Int J Infect DisInt. J. Infect. DisInternational Journal of" exact="Infectious" post="Diseases1201-97121878-3511The Authors. Published by Elsevier Ltd on behalf of"/>
  <result pre="Published by Elsevier Ltd on behalf of International Society for" exact="Infectious" post="Diseases. pmcid: 7128205S1201-9712(20)30076-X doi: 10.1016/j.ijid.2020.02.018 : Article Discovery and"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="and identify drug combinations for treatment of emerging and re-emerging" exact="viral" post="infections. Abstract Viral diseases are one of the leading"/>
  <result pre="combinations for treatment of emerging and re-emerging viral infections. Abstract" exact="Viral" post="diseases are one of the leading causes of morbidity"/>
  <result pre="and antiviral drugs are the most powerful tools to combat" exact="viral" post="diseases. However, broad-spectrum antiviral agents (BSAAs, i.e. compounds targeting"/>
  <result pre="(BSAAs, i.e. compounds targeting viruses belonging to two or more" exact="viral" post="families) could provide additional protection of the general population"/>
  <result pre="additional protection of the general population from emerging and re-emerging" exact="viral" post="diseases, reinforcing the arsenal of available antiviral options. Here,"/>
  <result pre="and identify drug combinations for treatment of emerging and re-emerging" exact="viral" post="infections as well as co-infections. Keywords Virus Antiviral drug"/>
  <result pre="identify drug combinations for treatment of emerging and re-emerging viral" exact="infections" post="as well as co-infections. Keywords Virus Antiviral drug Drug"/>
  <result pre="morbidity and mortality in the world (DALYs and Collaborators, 2018;" exact="Disease" post="et al., 2018; Howard and Fletcher, 2012; WHO, 2015)."/>
  <result pre="WHO, 2015). Antiviral drugs and vaccines are used to fight" exact="viral" post="infections in human (De Clercq and Li, 2016, Marston"/>
  <result pre="2015). Antiviral drugs and vaccines are used to fight viral" exact="infections" post="in human (De Clercq and Li, 2016, Marston et"/>
  <result pre="with recent outbreaks of Ebola, Zika, Dengue, influenza and other" exact="viral" post="infections, the discovery of novel host-directed agents, as well"/>
  <result pre="for generating additional value from an existing drug by targeting" exact="disease" post="other than that for which it was originally intended"/>
  <result pre="). Therefore, repositioning of launched or even failed drugs to" exact="viral" post="diseases provides unique translational opportunities, including a substantially higher"/>
  <result pre="of using safe-in-man BSAAs for treatment of emerging and re-emerging" exact="viral" post="infections as well as viral and bacterial co-infections. Discovery"/>
  <result pre="using safe-in-man BSAAs for treatment of emerging and re-emerging viral" exact="infections" post="as well as viral and bacterial co-infections. Discovery and"/>
  <result pre="treatment of emerging and re-emerging viral infections as well as" exact="viral" post="and bacterial co-infections. Discovery and development of safe-in-man BSAAs"/>
  <result pre="emerging and re-emerging viral infections as well as viral and" exact="bacterial" post="co-infections. Discovery and development of safe-in-man BSAAs Discovery of"/>
  <result pre="mock. Immortalized cancerous cell cultures and co-cultures, which express appropriate" exact="viral" post="receptors, are most commonly used in this first step."/>
  <result pre="panel) in animal models. If BSAA is repositioned from another" exact="disease" post="(i.e. its PK/PD and toxicity profiles are available for"/>
  <result pre="panel) Efficacy studies. If the drug is repositioned from another" exact="disease" post="(i.e. its safety profile in man is available) it"/>
  <result pre="it could bypass the PK and safety studies in man." exact="Viral" post="strains or cell lines expressing reporter proteins are also"/>
  <result pre="HIV-1 LTR promoter allowed quantitation of BSAA action on HIV-1" exact="infection" post="(tat-protein expression by integrated HIV-1 provirus) using firefly luciferase"/>
  <result pre="emetine also inhibits ZIKV, EBOV, RABV, CMV, HCoV-OC43 and HIV-1" exact="infections" post="(Chaves Valadao et al., 2015, MacGibeny et al., 2018,"/>
  <result pre="a promising safe-in-man BSAA candidate. Evaluation of BSAAs in human" exact="primary" post="cell culture and co-cultures Immortalized cell cultures/co-cultures and reporter"/>
  <result pre="primary cell culture and co-cultures Immortalized cell cultures/co-cultures and reporter" exact="viral" post="strains represent excellent model systems for the discovery of"/>
  <result pre="However, these genetically modified systems have certain limitations (attenuated or" exact="incomplete" post="virus replication cycle, accumulation of mutations during repeated cell"/>
  <result pre="repeated cell and virus passaging, defective innate immune responses and" exact="viral" post="counter-responses, etc.) (Carter and Shieh, 2015). Thereby, novel antiviral"/>
  <result pre="novel antiviral activities of BSAAs should be further validated in" exact="primary" post="human cells using different viral strains (including wild-type viruses),"/>
  <result pre="should be further validated in primary human cells using different" exact="viral" post="strains (including wild-type viruses), different viral loads, different times"/>
  <result pre="human cells using different viral strains (including wild-type viruses), different" exact="viral" post="loads, different times of compound addition, different endpoint measurements"/>
  <result pre="of compound addition, different endpoint measurements and compound concentration range." exact="Primary" post="cell cultures give more accurate images of drug responses"/>
  <result pre="therefore more closely recapitulate the physiological conditions observed in vivo." exact="Primary" post="cells are cells isolated directly from tissues or blood"/>
  <result pre="original phenotype. Peripheral blood mononuclear (PBMC), placental, amniotic and fetal" exact="primary" post="cultures as well as vaginal/cervical epithelial and male germ"/>
  <result pre="placental, amniotic and fetal primary cultures as well as vaginal/cervical" exact="epithelial" post="and male germ cells have been used intensively to"/>
  <result pre="2018, Rausch et al., 2017, Robinson et al., 2018). Although" exact="primary" post="cell cultures are relevant systems for validation of BSAAs,"/>
  <result pre="their use, such as ethical issues, purity of population of" exact="primary" post="cells, and limited shelf life of the cells. In"/>
  <result pre="as ethical issues, purity of population of primary cells, and" exact="limited" post="shelf life of the cells. In addition, age, race,"/>
  <result pre="et al., 2013). The obstacles associated with use of human" exact="primary" post="cell cultures can be bypassed using human embryonic stem"/>
  <result pre="efficacy of several BSAAs against HBV, ZIKV, CHIKV and HSV-1" exact="infections" post="(Table S1) (Ferreira et al., 2019, Iwasawa et al.,"/>
  <result pre="et al., 2017, Zhou et al., 2017). iPSCs, ESCs and" exact="primary" post="tissue cells can be used to generate complex cultures"/>
  <result pre="ESCs and iPSCs/ESCs-derived organoids have the same disadvantages as human" exact="primary" post="cells (genetic differences, line-to-line and organoid batch-to-batch variability). On"/>
  <result pre="same disadvantages as human primary cells (genetic differences, line-to-line and" exact="organoid" post="batch-to-batch variability). On the other hand, these models allow"/>
  <result pre="recently using human neural progenitor cells, human pluripotent stem cell-derived" exact="cortical" post="neural progenitor cells, and human induced neural stem cells,"/>
  <result pre="that they differ significantly from humans, with respect to symptoms," exact="disease" post="manifestation, susceptibility, immune responses, pathogenesis, and pharmacokinetics (Barré-Sinoussi and"/>
  <result pre="and neomycin were successfully tested against ZIKV, FLUAV, and HSV-2" exact="infections" post="in mice (Gopinath et al., 2018). Polyether antibiotic salinomycin"/>
  <result pre="the drugs in clinic. It is important, however, to differentiate" exact="acute" post="and chronic viral infections when repurposing BSAAs, given that"/>
  <result pre="in clinic. It is important, however, to differentiate acute and" exact="chronic" post="viral infections when repurposing BSAAs, given that drug concentrations"/>
  <result pre="clinic. It is important, however, to differentiate acute and chronic" exact="viral" post="infections when repurposing BSAAs, given that drug concentrations and"/>
  <result pre="It is important, however, to differentiate acute and chronic viral" exact="infections" post="when repurposing BSAAs, given that drug concentrations and duration"/>
  <result pre="issues should be considered. For phase II, patients with the" exact="viral" post="disease in question are invited to join the study,"/>
  <result pre="should be considered. For phase II, patients with the viral" exact="disease" post="in question are invited to join the study, where"/>
  <result pre="nitazoxanide, remdesivir and brincidofovir are under clinical investigations against different" exact="viral" post="infections (NCT03336619, NCT00302640, NCT03605862, NCT03719586, NCT01276756, NCT03905655, NCT01529073, NCT03395405,"/>
  <result pre="remdesivir and brincidofovir are under clinical investigations against different viral" exact="infections" post="(NCT03336619, NCT00302640, NCT03605862, NCT03719586, NCT01276756, NCT03905655, NCT01529073, NCT03395405, NCT03216967,"/>
  <result pre="is an injectable antiviral medication used as a treatment for" exact="CMV retinitis" post="in people with AIDS; ribavirin, also known as tribavirin,"/>
  <result pre="an injectable antiviral medication used as a treatment for CMV" exact="retinitis" post="in people with AIDS; ribavirin, also known as tribavirin,"/>
  <result pre="safe-in-man BSAAs, which inhibit 86 human viruses, belonging to 25" exact="viral" post="families. The BSAAs inhibit viral or host factors and"/>
  <result pre="human viruses, belonging to 25 viral families. The BSAAs inhibit" exact="viral" post="or host factors and block viral replication, reduce the"/>
  <result pre="families. The BSAAs inhibit viral or host factors and block" exact="viral" post="replication, reduce the viral burden to a level at"/>
  <result pre="viral or host factors and block viral replication, reduce the" exact="viral" post="burden to a level at which host immune responses"/>
  <result pre="the most abundant are nucleotide and nucleoside analogues which inhibit" exact="viral" post="RNA and DNA polymerases. Imatinib, erlotinib, gefitinib, and dasatinib,"/>
  <result pre="of the host targets (except Bcl-xL protein) are essential for" exact="viral" post="replication but redundant for the cell, which is critical"/>
  <result pre="for reducing putative toxicities associated with blocking cellular pathways. The" exact="limited" post="diversity of the targets and scaffolds could slow down"/>
  <result pre="clinical investigations. BSAAs as drug candidates for treatment of SARS-CoV-2" exact="infections" post="SARS-CoV-2 is a novel strain of coronaviruses which is"/>
  <result pre="coronaviruses which is associated with a cluster of cases of" exact="pneumonia" post="in China (Zhou et al., 2020). Coronaviruses (CoV) are"/>
  <result pre="HCoV-NL63 and HCoV-HKU1 strains are usually associated with mild, self-limiting" exact="upper" post="respiratory tract infections, such as the common cold. By"/>
  <result pre="and HCoV-HKU1 strains are usually associated with mild, self-limiting upper" exact="respiratory" post="tract infections, such as the common cold. By contrast,"/>
  <result pre="people infected with MERS-CoV, SASRS-CoV or SARS-CoV-2 could develop severe" exact="respiratory" post="illness, and many of the infected have died. No"/>
  <result pre="and drugs are available for prevention, prophylaxis and treatment of" exact="coronavirus infections" post="in humans (Eurosurveillance Editorial, 2020). However, safe-in-man BSAAs could"/>
  <result pre="drugs are available for prevention, prophylaxis and treatment of coronavirus" exact="infections" post="in humans (Eurosurveillance Editorial, 2020). However, safe-in-man BSAAs could"/>
  <result pre="shown to inhibit several corona- as well as some other" exact="viral" post="infections . Moreover, chloroquine and remdesivir were shown to"/>
  <result pre="to inhibit several corona- as well as some other viral" exact="infections" post=". Moreover, chloroquine and remdesivir were shown to effectively"/>
  <result pre="Moreover, chloroquine and remdesivir were shown to effectively inhibit SARS-CoV-2" exact="infection" post="in vitro. In addition, clinical investigations into the effectiveness"/>
  <result pre="clinical studies and become effective treatment of ZIKV and FLUAV" exact="infections" post="(Fu et al., 2016, Kuivanen et al., 2017). By"/>
  <result pre="line therapeutics against poorly characterized emerging viruses or re-emerging drug-resistant" exact="viral" post="strains. For example, a cocktail of nitazoxanide, favipiravir, and"/>
  <result pre="agents with dual activity could be used for treatment of" exact="viral" post="and bacterial co-infections or for the protection of patients"/>
  <result pre="dual activity could be used for treatment of viral and" exact="bacterial" post="co-infections or for the protection of patients from the"/>
  <result pre="bacterial co-infections or for the protection of patients from the" exact="secondary" post="infections. For example, azithromycin could be used against FLUAV"/>
  <result pre="and Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae" exact="infections" post="(NCT01779570) (Mandell et al., 2007). In addition, BSAAs showed"/>
  <result pre="ezetimibe and statins could be beneficial for treatment of both" exact="hypertension" post="and several viral infections in patients with these co-morbidities"/>
  <result pre="could be beneficial for treatment of both hypertension and several" exact="viral" post="infections in patients with these co-morbidities (NCT00908011, NCT00099684, NCT00843661,"/>
  <result pre="be beneficial for treatment of both hypertension and several viral" exact="infections" post="in patients with these co-morbidities (NCT00908011, NCT00099684, NCT00843661, NCT03490097,"/>
  <result pre="a pivotal role in the battle against emerging and re-emerging" exact="viral" post="diseases. Discovery of novel as well as repositioning existing"/>
  <result pre="have a global impact by decreasing morbidity and mortality from" exact="viral" post="and other diseases, maximizing the number of healthy life"/>
  <result pre="of Zika virus infectionCell Host Microbe20201625927027476412 BekermanE.EinavS.Infectious disease. Combating emerging" exact="viral" post="threatsScience348201528228325883340 BoonhamN.KreuzeJ.WinterS.van der VlugtR.BergervoetJ.TomlinsonJ.Methods in virus diagnostics: from ELISA"/>
  <result pre="generation sequencingVirus Res1862014203124361981 BoonyasuppayakornS.ReichertE.D.ManzanoM.NagarajanK.PadmanabhanR.Amodiaquine, an antimalarial drug, inhibits dengue virus" exact="type 2" post="replication and infectivityAntiviral Res106201412513424680954 BoslK.IanevskiA.ThanT.T.AndersenP.I.KuivanenS.TepporM.Common nodes of virus–host interaction"/>
  <result pre="of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteinsViruses92017 CairnsD.M.BoorguD.LevinM.KaplanD.L.Niclosamide rescues" exact="microcephaly" post="in a humanized in vivo model of Zika infection"/>
  <result pre="rescues microcephaly in a humanized in vivo model of Zika" exact="infection" post="using human induced neural stem cellsBiol Open72018 CarterM.ShiehJ.Chapter 14"/>
  <result pre="by interfering with reverse transcriptase activityMolecules202015114741148926111177 ChengY.S.WilliamsonP.R.ZhengW.Improving therapy of severe" exact="infections" post="through drug repurposing of synergistic combinationsCurr Opin Pharmacol482019929831454708 DALYs,"/>
  <result pre="territories, 1990-2017: a systematic analysis for the Global Burden of" exact="Disease" post="Study 2017Lancet39220181859192230415748 De ClercqE.LiG.Approved antiviral drugs over the past"/>
  <result pre="territories, 1990-2017: a systematic analysis for the Global Burden of" exact="Disease" post="Study 2017Lancet39220181789185830496104 Eurosurveillance EditorialT.Note from the editors: World Health"/>
  <result pre="of international concernEuro Surveill2020 FangJ.SunL.PengG.XuJ.ZhouR.CaoS.Identification of three antiviral inhibitors against" exact="Japanese encephalitis" post="virus from library of pharmacologically active compounds 1280PLoS One82013e78425"/>
  <result pre="international concernEuro Surveill2020 FangJ.SunL.PengG.XuJ.ZhouR.CaoS.Identification of three antiviral inhibitors against Japanese" exact="encephalitis" post="virus from library of pharmacologically active compounds 1280PLoS One82013e78425"/>
  <result pre="Boas HoelzL.BastosM.M.Beyond members of the flaviviridae family, sofosbuvir also inhibits" exact="chikungunya" post="virus replicationAntimicrob Agents Chemother632019 FinkS.L.VojtechL.WagonerJ.SlivinskiN.S.J.JacksonK.J.WangR.The antiviral drug arbidol inhibits"/>
  <result pre="drug arbidol inhibits Zika virusSci Rep82018898929895962 FischerC.TorresM.C.PatelP.Moreira-SotoA.GouldE.A.CharrelR.N.Lineage-specific real-time RT-PCR for" exact="yellow fever" post="virus outbreak surveillance, BrazilEmerg Infect Dis23201718671871 FoucquierJ.GuedjM.Analysis of drug"/>
  <result pre="GopinathS.KimM.V.RakibT.WongP.W.van ZandtM.BarryN.A.Topical application of aminoglycoside antibiotics enhances host resistance to" exact="viral" post="infections in a microbiota-independent mannerNat Microbiol3201861162129632368 HabjanM.PenskiN.SpiegelM.WeberF.T7 RNA polymerase-dependent"/>
  <result pre="ZandtM.BarryN.A.Topical application of aminoglycoside antibiotics enhances host resistance to viral" exact="infections" post="in a microbiota-independent mannerNat Microbiol3201861162129632368 HabjanM.PenskiN.SpiegelM.WeberF.T7 RNA polymerase-dependent and"/>
  <result pre="HabjanM.PenskiN.SpiegelM.WeberF.T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of" exact="Rift Valley fever" post="virusJ Gen Virol8920082157216618753225 HaeseN.N.BroeckelR.M.HawmanD.W.HeiseM.T.MorrisonT.E.StreblowD.N.Animal models of Chikungunya virus infection"/>
  <result pre="of Rift Valley fever virusJ Gen Virol8920082157216618753225 HaeseN.N.BroeckelR.M.HawmanD.W.HeiseM.T.MorrisonT.E.StreblowD.N.Animal models of" exact="Chikungunya virus infection" post="and diseaseJ Infect Dis2142016S482S48727920178 HowardC.R.FletcherN.F.Emerging virus diseases: can we"/>
  <result pre="Rift Valley fever virusJ Gen Virol8920082157216618753225 HaeseN.N.BroeckelR.M.HawmanD.W.HeiseM.T.MorrisonT.E.StreblowD.N.Animal models of Chikungunya" exact="virus infection" post="and diseaseJ Infect Dis2142016S482S48727920178 HowardC.R.FletcherN.F.Emerging virus diseases: can we"/>
  <result pre="Valley fever virusJ Gen Virol8920082157216618753225 HaeseN.N.BroeckelR.M.HawmanD.W.HeiseM.T.MorrisonT.E.StreblowD.N.Animal models of Chikungunya virus" exact="infection" post="and diseaseJ Infect Dis2142016S482S48727920178 HowardC.R.FletcherN.F.Emerging virus diseases: can we"/>
  <result pre="activities of safe-in-human broad-spectrum antiviral agentsAntiviral Res154201817418229698664 IwasawaC.TamuraR.SugiuraY.SuzukiS.KuzumakiN.NaritaM.Increased cytotoxicity of" exact="herpes" post="simplex virus thymidine kinase expression in human induced pluripotent"/>
  <result pre="induced pluripotent stem cellsInt J Mol Sci202019 JangY.ShinJ.S.YoonY.S.GoY.Y.LeeH.W.KwonO.S.Salinomycin inhibits influenza" exact="virus infection" post="by disrupting endosomal acidification and viral matrix protein 2"/>
  <result pre="pluripotent stem cellsInt J Mol Sci202019 JangY.ShinJ.S.YoonY.S.GoY.Y.LeeH.W.KwonO.S.Salinomycin inhibits influenza virus" exact="infection" post="by disrupting endosomal acidification and viral matrix protein 2"/>
  <result pre="JangY.ShinJ.S.YoonY.S.GoY.Y.LeeH.W.KwonO.S.Salinomycin inhibits influenza virus infection by disrupting endosomal acidification and" exact="viral" post="matrix protein 2 functionJ Virol922018 JupilleH.J.OkoL.StoermerK.A.HeiseM.T.MahalingamS.GunnB.M.Mutations in nsP1 and"/>
  <result pre="PE2 are critical determinants of Ross River virus-induced musculoskeletal inflammatory" exact="disease" post="in a mouse modelVirology410201121622721131014 JurgeitA.McDowellR.MoeseS.MeldrumE.SchwendenerR.GreberU.F.Niclosamide is a proton carrier"/>
  <result pre="broad antiviral effectsPLoS Pathog82012e1002976 KaoJ.C.HuangFuW.C.TsaiT.T.HoM.R.JhanM.K.ShenT.J.The antiparasitic drug niclosamide inhibits dengue" exact="virus infection" post="by interfering with endosomal acidification independent of mTORPLoS Negl"/>
  <result pre="antiviral effectsPLoS Pathog82012e1002976 KaoJ.C.HuangFuW.C.TsaiT.T.HoM.R.JhanM.K.ShenT.J.The antiparasitic drug niclosamide inhibits dengue virus" exact="infection" post="by interfering with endosomal acidification independent of mTORPLoS Negl"/>
  <result pre="Dis122018e0006715 KashiwaseH.MomotaK.OhmineT.KomaiT.KimuraT.KatsubeT.A new fluoroquinolone derivative exhibits inhibitory activity against human" exact="immunodeficiency" post="virus type 1 replicationChemotherapy4519994855 KimS.ChenJ.ChengT.GindulyteA.HeJ.HeS.PubChem 2019 update: improved access"/>
  <result pre="new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus" exact="type 1" post="replicationChemotherapy4519994855 KimS.ChenJ.ChengT.GindulyteA.HeJ.HeS.PubChem 2019 update: improved access to chemical dataNucleic"/>
  <result pre="novel three-dimensional cell culture method enhances antiviral drug screening in" exact="primary" post="human cellsAntiviral Res1502018202929224735 KonigA.YangJ.JoE.ParkK.H.P.KimH.ThanT.T.Efficient long-term amplification of hepatitis B"/>
  <result pre="screening in primary human cellsAntiviral Res1502018202929224735 KonigA.YangJ.JoE.ParkK.H.P.KimH.ThanT.T.Efficient long-term amplification of" exact="hepatitis" post="B virus isolates after infection of slow proliferating HepG2-NTCP"/>
  <result pre="Res1502018202929224735 KonigA.YangJ.JoE.ParkK.H.P.KimH.ThanT.T.Efficient long-term amplification of hepatitis B virus isolates after" exact="infection" post="of slow proliferating HepG2-NTCP cellsJ Hepatol71201928930031077792 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.Obatoclax, saliphenylhalamide"/>
  <result pre="HepG2-NTCP cellsJ Hepatol71201928930031077792 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika" exact="virus infection" post="in vitro and differentially affect cellular signaling, transcription and"/>
  <result pre="cellsJ Hepatol71201928930031077792 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus" exact="infection" post="in vitro and differentially affect cellular signaling, transcription and"/>
  <result pre="real-time RT-PCR for simultaneous detection of four most common avian" exact="respiratory" post="virusesVirology5152018293729223788 LandryM.L.Nucleic acid hybridization in viral diagnosisClin Biochem2319902672772225455 LankoK.EggermontK.PatelA.KapteinS.DelangL.VerfaillieC.M.Replication"/>
  <result pre="four most common avian respiratory virusesVirology5152018293729223788 LandryM.L.Nucleic acid hybridization in" exact="viral" post="diagnosisClin Biochem2319902672772225455 LankoK.EggermontK.PatelA.KapteinS.DelangL.VerfaillieC.M.Replication of the Zika virus in different"/>
  <result pre="diagnosisClin Biochem2319902672772225455 LankoK.EggermontK.PatelA.KapteinS.DelangL.VerfaillieC.M.Replication of the Zika virus in different iPSC-derived" exact="neuronal" post="cells and implications to assess efficacy of antiviralsAntiviral Res1452017828628736077"/>
  <result pre="responses in human dendritic cellsScience34320141246980 LiC.DengY.Q.WangS.MaF.AliyariR.HuangX.Y.25-Hydroxycholesterol protects host against Zika" exact="virus infection" post="and its associated microcephaly in a mouse modelImmunity46201744645628314593 LouzD.BergmansH.E.LoosB.P.HoebenR.C.Animal"/>
  <result pre="in human dendritic cellsScience34320141246980 LiC.DengY.Q.WangS.MaF.AliyariR.HuangX.Y.25-Hydroxycholesterol protects host against Zika virus" exact="infection" post="and its associated microcephaly in a mouse modelImmunity46201744645628314593 LouzD.BergmansH.E.LoosB.P.HoebenR.C.Animal"/>
  <result pre="LiC.DengY.Q.WangS.MaF.AliyariR.HuangX.Y.25-Hydroxycholesterol protects host against Zika virus infection and its associated" exact="microcephaly" post="in a mouse modelImmunity46201744645628314593 LouzD.BergmansH.E.LoosB.P.HoebenR.C.Animal models in virus research:"/>
  <result pre="in virus research: their utility and limitationsCrit Rev Microbiol39201332536122978742 MacGibenyM.A.KoyuncuO.O.WirblichC.SchnellM.J.EnquistL.W.Retrograde" exact="axonal" post="transport of rabies virus is unaffected by interferon treatment"/>
  <result pre="their utility and limitationsCrit Rev Microbiol39201332536122978742 MacGibenyM.A.KoyuncuO.O.WirblichC.SchnellM.J.EnquistL.W.Retrograde axonal transport of" exact="rabies" post="virus is unaffected by interferon treatment but blocked by"/>
  <result pre="treatment but blocked by emetine locally in axonsPLoS Pathog142018e1007188 MandellL.A.WunderinkR.G.AnzuetoA.BartlettJ.G.CampbellG.D.DeanN.C.Infectious" exact="Diseases" post="Society of America/American Thoracic Society consensus guidelines on the"/>
  <result pre="emetine locally in axonsPLoS Pathog142018e1007188 MandellL.A.WunderinkR.G.AnzuetoA.BartlettJ.G.CampbellG.D.DeanN.C.Infectious Diseases Society of America/American" exact="Thoracic" post="Society consensus guidelines on the management of community-acquired pneumonia"/>
  <result pre="America/American Thoracic Society consensus guidelines on the management of community-acquired" exact="pneumonia" post="in adultsClin Infect Dis44Suppl 22007S277217278083 MarstonH.D.FolkersG.K.MorensD.M.FauciA.S.Emerging viral diseases: confronting"/>
  <result pre="management of community-acquired pneumonia in adultsClin Infect Dis44Suppl 22007S277217278083 MarstonH.D.FolkersG.K.MorensD.M.FauciA.S.Emerging" exact="viral" post="diseases: confronting threats with new technologiesSci Transl Med62014253ps210 MazzonM.Ortega-PrietoA.M.ImrieD.LuftC.HessL.CziesoS.Identification"/>
  <result pre="technologiesSci Transl Med62014253ps210 MazzonM.Ortega-PrietoA.M.ImrieD.LuftC.HessL.CziesoS.Identification of broad-spectrum antiviral compounds by targeting" exact="viral" post="entryViruses112019 MeneghiniK.A.HamasakiD.I.The electroretinogram of the iguana and Tokay geckoVision"/>
  <result pre="geckoVision Res719672432515613294 MontoyaM.C.KrysanD.J.Repurposing estrogen receptor antagonists for the treatment of" exact="infectious" post="diseaseMBio92018 MorrisonT.E.DiamondM.S.Animal models of Zika virus infection, pathogenesis, and"/>
  <result pre="for the treatment of infectious diseaseMBio92018 MorrisonT.E.DiamondM.S.Animal models of Zika" exact="virus infection," post="pathogenesis, and immunityJ Virol201791 MukhopadhyayR.RoyS.VenkatadriR.SuY.P.YeW.BarnaevaE.Efficacy and mechanism of action"/>
  <result pre="M., 2019. Drug repurposing approaches for the treatment of influenza" exact="viral" post="infection: reviving old drugs to fight against a long-lived"/>
  <result pre="epitheliumEBioMedicine39201931533130579862 SmeeD.F.BarnardD.L.Methods for evaluation of antiviral efficacy against influenza virus" exact="infections" post="in animal modelsMethods Mol Biol (Clifton, N.J.)10302013407425 SoderholmS.KainovD.E.OhmanT.DenisovaO.V.SchepensB.KulesskiyE.Phosphoproteomics to"/>
  <result pre="(Clifton, N.J.)10302013407425 SoderholmS.KainovD.E.OhmanT.DenisovaO.V.SchepensB.KulesskiyE.Phosphoproteomics to characterize host response during influenza a" exact="virus infection" post="of human macrophagesMol Cell Proteomics1520163203321927486199 StachulskiA.V.PidathalaC.RowE.C.SharmaR.BerryN.G.LawrensonA.S.Thiazolides as novel antiviral"/>
  <result pre="N.J.)10302013407425 SoderholmS.KainovD.E.OhmanT.DenisovaO.V.SchepensB.KulesskiyE.Phosphoproteomics to characterize host response during influenza a virus" exact="infection" post="of human macrophagesMol Cell Proteomics1520163203321927486199 StachulskiA.V.PidathalaC.RowE.C.SharmaR.BerryN.G.LawrensonA.S.Thiazolides as novel antiviral"/>
  <result pre="Cell Proteomics1520163203321927486199 StachulskiA.V.PidathalaC.RowE.C.SharmaR.BerryN.G.LawrensonA.S.Thiazolides as novel antiviral agents. 2. Inhibition of" exact="hepatitis" post="C virus replicationJ Med Chem5420118670868022059983 TaylorG.Animal models of respiratory"/>
  <result pre="of hepatitis C virus replicationJ Med Chem5420118670868022059983 TaylorG.Animal models of" exact="respiratory" post="syncytial virus infectionVaccine35201746948027908639 ThangavelR.R.BouvierN.M.Animal models for influenza virus pathogenesis,"/>
  <result pre="UrsuO.HolmesJ.BologaC.G.YangJ.J.MathiasS.L.StathiasV.DrugCentral 2018: an updateNucleic Acids Res472019D963D97030371892 UttA.QuirinT.SaulS.HellstromK.AholaT.MeritsA.Versatile trans-replication systems for" exact="chikungunya" post="virus allow functional analysis and tagging of every replicase"/>
  <result pre="replicase proteinPLoS One112016e0151616 WangY.M.LuJ.W.LinC.C.ChinY.F.WuT.Y.LinL.I.Antiviral activities of niclosamide and nitazoxanide against" exact="chikungunya" post="virus entry and transmissionAntiviral Res1352016819027742486 WatanabeM.ButhJ.E.VishlaghiN.de la Torre-UbietaL.TaxidisJ.KhakhB.S.Self-organized cerebral"/>
  <result pre="against chikungunya virus entry and transmissionAntiviral Res1352016819027742486 WatanabeM.ButhJ.E.VishlaghiN.de la Torre-UbietaL.TaxidisJ.KhakhB.S.Self-organized" exact="cerebral" post="organoids with human-specific features predict effective drugs to combat"/>
  <result pre="the DrugBank database for 2018Nucleic Acids Res462018D1074D108229126136 WuC.J.JanJ.T.ChenC.M.HsiehH.P.HwangD.R.LiuH.W.Inhibition of severe" exact="acute" post="respiratory syndrome coronavirus replication by niclosamideAntimicrob Agents Chemother4820042693269615215127 XiaY.CarpentierA.ChengX.BlockP.D.ZhaoY.ZhangZ.Human"/>
  <result pre="DrugBank database for 2018Nucleic Acids Res462018D1074D108229126136 WuC.J.JanJ.T.ChenC.M.HsiehH.P.HwangD.R.LiuH.W.Inhibition of severe acute" exact="respiratory" post="syndrome coronavirus replication by niclosamideAntimicrob Agents Chemother4820042693269615215127 XiaY.CarpentierA.ChengX.BlockP.D.ZhaoY.ZhangZ.Human stem"/>
  <result pre="database for 2018Nucleic Acids Res462018D1074D108229126136 WuC.J.JanJ.T.ChenC.M.HsiehH.P.HwangD.R.LiuH.W.Inhibition of severe acute respiratory" exact="syndrome" post="coronavirus replication by niclosamideAntimicrob Agents Chemother4820042693269615215127 XiaY.CarpentierA.ChengX.BlockP.D.ZhaoY.ZhangZ.Human stem cell-derived"/>
  <result pre="Agents Chemother4820042693269615215127 XiaY.CarpentierA.ChengX.BlockP.D.ZhaoY.ZhangZ.Human stem cell-derived hepatocytes as a model for" exact="hepatitis" post="B virus infection, spreading and virus-host interactionsJ Hepatol66201749450327746336 XingL.WangS.HuQ.LiJ.ZengY.Comparison"/>
  <result pre="XiaY.CarpentierA.ChengX.BlockP.D.ZhaoY.ZhangZ.Human stem cell-derived hepatocytes as a model for hepatitis B" exact="virus infection," post="spreading and virus-host interactionsJ Hepatol66201749450327746336 XingL.WangS.HuQ.LiJ.ZengY.Comparison of three quantification"/>
  <result pre="anti-HIV-1 agentsJ Virol Methods2332016566127016178 XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.Identification of small-molecule inhibitors of Zika" exact="virus infection" post="and induced neural cell death via a drug repurposing"/>
  <result pre="agentsJ Virol Methods2332016566127016178 XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
  <result pre="neural cell death via a drug repurposing screenNat Med2220161101110727571349 XuY.P.QiuY.ZhangB.ChenG.ChenQ.WangM.Zika" exact="virus infection" post="induces RNAi-mediated antiviral immunity in human neural progenitors and"/>
  <result pre="cell death via a drug repurposing screenNat Med2220161101110727571349 XuY.P.QiuY.ZhangB.ChenG.ChenQ.WangM.Zika virus" exact="infection" post="induces RNAi-mediated antiviral immunity in human neural progenitors and"/>
  <result pre="and brain organoidsCell Res29201926527330814679 YangS.XuM.LeeE.M.GorshkovK.ShiryaevS.A.HeS.Emetine inhibits Zika and Ebola virus" exact="infections" post="through two molecular mechanisms: inhibiting viral replication and decreasing"/>
  <result pre="Zika and Ebola virus infections through two molecular mechanisms: inhibiting" exact="viral" post="replication and decreasing viral entryCell Discov420183129872540 YinY.BijveldsM.DangW.XuL.van der EijkA.A.KnippingK.Modeling"/>
  <result pre="infections through two molecular mechanisms: inhibiting viral replication and decreasing" exact="viral" post="entryCell Discov420183129872540 YinY.BijveldsM.DangW.XuL.van der EijkA.A.KnippingK.Modeling rotavirus infection and antiviral"/>
  <result pre="replication and decreasing viral entryCell Discov420183129872540 YinY.BijveldsM.DangW.XuL.van der EijkA.A.KnippingK.Modeling rotavirus" exact="infection" post="and antiviral therapy using primary intestinal organoidsAntiviral Res123201512013126408355 YinY.ChenS.HakimM.S.WangW.XuL.DangW.6-Thioguanine"/>
  <result pre="Discov420183129872540 YinY.BijveldsM.DangW.XuL.van der EijkA.A.KnippingK.Modeling rotavirus infection and antiviral therapy using" exact="primary" post="intestinal organoidsAntiviral Res123201512013126408355 YinY.ChenS.HakimM.S.WangW.XuL.DangW.6-Thioguanine inhibits rotavirus replication through suppression"/>
  <result pre="of Rac1 GDP/GTP cyclingAntiviral Res15620189210129920300 YinY.WangY.DangW.XuL.SuJ.ZhouX.Mycophenolic acid potently inhibits rotavirus" exact="infection" post="with a high barrier to resistance developmentAntiviral Res1332016414927468950 YoungD.D.ConnellyC.M.GrohmannC.DeitersA.Small"/>
  <result pre="molecule modifiers of microRNA miR-122 function for the treatment of" exact="hepatitis" post="C virus infection and hepatocellular carcinomaJ Am Chem Soc13220107976798120527935"/>
  <result pre="of microRNA miR-122 function for the treatment of hepatitis C" exact="virus infection" post="and hepatocellular carcinomaJ Am Chem Soc13220107976798120527935 ZhangY.H.ZhaoY.LiN.PengY.C.GiannoulatouE.JinR.H.Interferon-induced transmembrane protein-3"/>
  <result pre="microRNA miR-122 function for the treatment of hepatitis C virus" exact="infection" post="and hepatocellular carcinomaJ Am Chem Soc13220107976798120527935 ZhangY.H.ZhaoY.LiN.PengY.C.GiannoulatouE.JinR.H.Interferon-induced transmembrane protein-3"/>
  <result pre="Chinese individualsNat Commun42013141823361009 ZhengW.SunW.SimeonovA.Drug repurposing screens and synergistic drug-combinations for" exact="infectious" post="diseasesBr J Pharmacol175201818119128685814 ZhouL.PengR.ZhangR.LiJ.The applications of CRISPR/Cas system in"/>
  <result pre="of CRISPR/Cas system in molecular detectionJ Cell Mol Med2220185807581530338908 ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="screening in hPSC-neural progenitors identifies drug candidates that inhibit Zika" exact="virus infection" post="in fetal-like organoids and adult brainCell Stem Cell212017274–283.e275 Appendix"/>
  <result pre="in hPSC-neural progenitors identifies drug candidates that inhibit Zika virus" exact="infection" post="in fetal-like organoids and adult brainCell Stem Cell212017274–283.e275 Appendix"/>
  <result pre="candidates that inhibit Zika virus infection in fetal-like organoids and" exact="adult" post="brainCell Stem Cell212017274–283.e275 Appendix A Supplementary data The following"/>
 </snippets>
</snippetsTree>
